Literature DB >> 24935408

Immunoregulation effects of bone marrow-derived mesenchymal stem cells in xenogeneic acellular nerve grafts transplant.

Lihong Fan1, Zefeng Yu, Jia Li, Xiaoqian Dang, Kunzheng Wang.   

Abstract

This study evaluated whether bone marrow-derived mesenchymal stem cells (BM-MSCs) combined with xenogeneic acellular nerve grafts (xANGs) would reduce the inflammation reaction of xANGs transplantation. BM-MSCs were extracted, separated, purified, and cultured from the bone marrow of rats. Then BM-MSCs were seeded into 5 mm xANGs as experimental group, while xANGs group was chosen as control. Subcutaneous implantation and nerve grafts transplantation were done in this study. Walking-track tests, electrophysiological tests, H&amp;E staining, and immunostaining of CD4, CD8, and CD68 of subcutaneous implantations, cytokine concentrations of IL-2, IL-10, IFN-γ and TNF-α in lymphocytes supernatants and serum of the two groups were evaluated. Walking-track tests and electrophysiological tests suggested the group of BM-MSCs with xANGs obtained better results than xANGs group (P < 0.05). H&amp;E staining and immunostaining of CD4, CD8, and CD68 of subcutaneous implantations showed there were less inflammatory cells in the group of BM-MSCs when compared with the xANGs group. The cytokine concentrations of IL-2, IFN-γ, and TNF-α in BM-MSCs group were lower than xANGs group in lymphocytes supernatants and serum (P < 0.05). However, IL-10 concentrations in BM-MSCs group were higher than xANGs group (P < 0.05). xANG with BM-MSCs showed better nerve repair function when compared with xANG group. Furthermore, xANG with BM-MSCs showed less inflammatory reaction which might indicate the reason of its better nerve regeneration.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24935408     DOI: 10.1007/s10571-014-0076-3

Source DB:  PubMed          Journal:  Cell Mol Neurobiol        ISSN: 0272-4340            Impact factor:   5.046


  50 in total

1.  Distribution of the CD68 macrophage/myeloid associated antigen.

Authors:  K A Pulford; A Sipos; J L Cordell; W P Stross; D Y Mason
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

2.  A new approach to assess function after sciatic nerve lesion in the mouse - adaptation of the sciatic static index.

Authors:  Abrahão Fontes Baptista; Joyce Rios de Souza Gomes; Júlia Teixeria Oliveira; Soraia Moreira Garzedim Santos; Marcos André Vannier-Santos; Ana Maria Blanco Martinez
Journal:  J Neurosci Methods       Date:  2007-01-03       Impact factor: 2.390

3.  Xenogeneic extracellular matrix grafts elicit a TH2-restricted immune response.

Authors:  A J Allman; T B McPherson; S F Badylak; L C Merrill; B Kallakury; C Sheehan; R H Raeder; D W Metzger
Journal:  Transplantation       Date:  2001-06-15       Impact factor: 4.939

4.  Sciatic function index, nerve conduction tests, muscle contraction, and axon morphometry as indicators of regeneration.

Authors:  F Kanaya; J C Firrell; W C Breidenbach
Journal:  Plast Reconstr Surg       Date:  1996-12       Impact factor: 4.730

5.  A randomized controlled multicenter study comparing recombinant interleukin 2 (rIL-2) in conjunction with recombinant interferon alpha (IFN-alpha) versus no immunotherapy for patients with malignant lymphoma postautologous stem cell transplantation.

Authors:  Arnon Nagler; Raanan Berger; Aliza Ackerstein; Jaroslaw A Czyz; Jose Luis Diez-Martin; Elizabeth Naparstek; Reuven Or; Shlomit Gan; Avichai Shimoni; Shimon Slavin
Journal:  J Immunother       Date:  2010-04       Impact factor: 4.456

6.  Human mesenchymal stem cells modulate allogeneic immune cell responses.

Authors:  Sudeepta Aggarwal; Mark F Pittenger
Journal:  Blood       Date:  2004-10-19       Impact factor: 22.113

7.  Repair of extended peripheral nerve lesions in rhesus monkeys using acellular allogenic nerve grafts implanted with autologous mesenchymal stem cells.

Authors:  Jun Hu; Qing-Tang Zhu; Xiao-Lin Liu; Yang-bin Xu; Jia-Kai Zhu
Journal:  Exp Neurol       Date:  2007-01-10       Impact factor: 5.330

8.  IFN-gamma activation of mesenchymal stem cells for treatment and prevention of graft versus host disease.

Authors:  David Polchert; Justin Sobinsky; Gw Douglas; Martha Kidd; Ada Moadsiri; Eduardo Reina; Kristyn Genrich; Swati Mehrotra; Suman Setty; Brett Smith; Amelia Bartholomew
Journal:  Eur J Immunol       Date:  2008-06       Impact factor: 5.532

9.  IFN-gamma and TNF-alpha differentially regulate immunomodulation by murine mesenchymal stem cells.

Authors:  Karen English; Frank P Barry; Ciara P Field-Corbett; Bernard P Mahon
Journal:  Immunol Lett       Date:  2007-04-26       Impact factor: 3.685

Review 10.  Mesenchymal stem cells and autoimmune diseases.

Authors:  Francesco Dazzi; Mauro Krampera
Journal:  Best Pract Res Clin Haematol       Date:  2011-02-23       Impact factor: 3.020

View more
  4 in total

1.  Effect of Bone Morphogenetic Protein 6 on Immunomodulatory Functions of Salivary Gland-Derived Mesenchymal Stem Cells in Sjögren's Syndrome.

Authors:  Junji Xu; Yingying Su; Lei Hu; Alexander Cain; Yi Gu; Bowen Liu; Ruiqing Wu; Songlin Wang; Hao Wang
Journal:  Stem Cells Dev       Date:  2018-11-15       Impact factor: 3.272

2.  Bone Morphogenetic Protein 6 Inhibits the Immunomodulatory Property of BMMSCs via Id1 in Sjögren's Syndrome.

Authors:  Yingying Su; Yi Gu; Ruiqing Wu; Hao Wang
Journal:  Stem Cells Int       Date:  2018-08-02       Impact factor: 5.443

Review 3.  Nerve Repair Using Decellularized Nerve Grafts in Rat Models. A Review of the Literature.

Authors:  Arianna B Lovati; Daniele D'Arrigo; Simonetta Odella; Pierluigi Tos; Stefano Geuna; Stefania Raimondo
Journal:  Front Cell Neurosci       Date:  2018-11-19       Impact factor: 5.505

Review 4.  Immunomodulatory effects of mesenchymal stem cells in peripheral nerve injury.

Authors:  Xiangling Li; Yanjun Guan; Chaochao Li; Tieyuan Zhang; Fanqi Meng; Jian Zhang; Junyang Li; Shengfeng Chen; Qi Wang; Yi Wang; Jiang Peng; Jinshu Tang
Journal:  Stem Cell Res Ther       Date:  2022-01-15       Impact factor: 6.832

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.